Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00856869
• Date of registration: 04/03/2009
• Primary sponsor: Norgine
• Public title: Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
• Scientific title: A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.
• Date of first enrolment: August 2004
• Target sample size: 52
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00856869
• Study type: Interventional
• Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Countries of recruitment

Bulgaria

Contacts

• Name: Hans-Jürgen Gruss, MD
• Affiliation: Norgine

• Name: Zahariy Krastev, MD
• Affiliation: St. Ivan Rilski's University Hospital

Key inclusion & exclusion criteria

Inclusion Criteria:

General - all subjects

1. Males or females (females of non-childbearing potential or of childbearing potential
while taking medically appropriate contraception)

2. Caucasian

3. BMI: between 19 and 34 kg.m-2

4. BW: between 45 and 110 kg

5. willing and able to provide informed consent Healthy volunteers (group N)

6. Age: 18 - 40 years (inclusive) e.g. > 60 years

7. Assessed as healthy based on the pre study examination Hepatic cirrhosis

8. Age: 18 - 75 years

9. stable compensated liver cirrhosis (cryptogenic, posthepatic, alcoholic) with
histo-logical or macroscopic (e.g. laparascopy, biopsy, ultrasound sonography or
other adequate imaging techniques) confirmation Nonalcoholic steatohepatitis (NASH)

10. Age: 18 - 75 years

11. Diagnosis of NASH confirmed by liver biopsy

Exclusion Criteria:

General - all subjects

1. Previous participation in the trial

2. Participant in any other trial during the last 90 days

3. Donation of blood during the last 60 days or a history of blood loss exceeding 450 mL
within the last 3 months

4. History of any clinically relevant allergy

5. Uncontrolled diabetes mellitus or any further intolerability of the Galactose test

6. Presence of acute or chronic infection

7. Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or
< 50 mmHg

8. Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and >
460 msec in females in particular

9. Clinically relevant ECG-abnormalities that constitute a contraindication for the
Lido-cain-MEG'-X-test

10. Positive HIV test

11. Positive alcohol or urine drug test on recruitment

12. Daily use of > 30 gr alcohol

13. Smoking more than 15 cigarettes/day or equivalent of other tobacco products

14. Use of prohibited medication

15. Suspicion or evidence that the subject is not trustworthy and reliable

16. Suspicion or evidence that the subject is not able to make a free consent or to
under-stand the information in this regard

General - all females

17. Positive pregnancy test

18. Lactating

19. Not using appropriate contraception in premenopausal women All healthy subjects

20. Presence or history of any relevant comorbidity (list of past and present diseases
will be reviewed by an expert panel)

21. Presence of any relevant abnormality in the laboratory safety tests, especially low
haemoglobin, increased liver enzymes, reduced serum creatinine (laboratory test
abnormalities will be reviewed by an expert panel)

22. Positive serology for HBsAg, anti HBc and anti HCV

23. History of alcohol and/or drug abuse.

Patients with hepatic disease

24. Biliary liver cirrhosis

25. Liver impairment due to space-occupying processes (e.g. carcinoma)

26. State after liver transplantation or patient scheduled for liver transplantation

27. Fluctuating or rapidly deteriorating hepatic function

28. Significant bleeding diathesis

29. Oesophageal bleeding within the last 8 weeks before study entry

30. Ascites > 6 L on abdominal US

31. Number Connection test: time to connect 25 consecutive numbers > 30 sec

32. Presence or history of any relevant comorbidity other than hepatic disease (list of
past and present diseases will be reviewed by an expert panel)

33. Clinically relevant abnormal laboratory values other than those associated or
sufficiently explained by the existing liver disease (laboratory test abnormalities
will be reviewed by an expert panel)

34. History of drug or alcohol abuse within 2 months prior to dosing



Age minimum: 18 Years
Age maximum: 75 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Hepatic Cirrhosis

Nonalcoholic Steatohepatitis

Intervention(s)

Drug: NRL972

Primary Outcome(s)

Clearance of NRL972 after a standard meal and while fasted in healthy volunteers, patients with NASH and patients with hepatic cirrhosis. [Time Frame: Up to 4 hours post administration of NRL972]

Secondary Outcome(s)

Adverse events and changes in physical findings from baseline [Time Frame: Up to 4 hours post-dosing]

Changes in haematology, clinical chemistry, urinalysis [Time Frame: Up to 4 hours post-dosing]

Effects of vital signs: blood pressure, pulse rate [Time Frame: Up to 4 hours post-dosing]

Effects on electrocardiogram [Time Frame: Up to 4 hours post-dosing]

Secondary ID(s)

NRL972-02/2003(ACPS)

Source(s) of Monetary Support

Please refer to primary and secondary sponsors